CLINICAL TRIALS PROFILE FOR OPTIMARK IN PLASTIC CONTAINER

All Clinical Trials for OPTIMARK IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00530101 ↗	The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity	Completed	Mallinckrodt	Phase 1	2004-07-01	The purpose of this research study is to evaluate MR imaging in subjects receiving doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA scans. This research study is expected to enroll approximately 10 subjects over 12 months at the University of Miami / Miller School of Medicine.
NCT00530101 ↗	The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity	Completed	University of Miami	Phase 1	2004-07-01	The purpose of this research study is to evaluate MR imaging in subjects receiving doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA scans. This research study is expected to enroll approximately 10 subjects over 12 months at the University of Miami / Miller School of Medicine.
NCT00862459 ↗	Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)	Completed	Bayer	Phase 2	2005-08-01	The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine. The results of the MRI with Gadavist Injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with OptiMARK.

Clinical Trial Conditions for OPTIMARK IN PLASTIC CONTAINER

Condition Name

Condition Name for OPTIMARK IN PLASTIC CONTAINER
Intervention	Trials
Breast Cancer	1
Pathological Processes	1
Spinal Cord Diseases	1

Condition MeSH

Condition MeSH for OPTIMARK IN PLASTIC CONTAINER
Intervention	Trials
Pathologic Processes	1
Spinal Cord Diseases	1
Brain Diseases	1

Clinical Trial Locations for OPTIMARK IN PLASTIC CONTAINER

Trials by Country

Trials by Country for OPTIMARK IN PLASTIC CONTAINER
Location	Trials
United States	28
Colombia	3
Argentina	2
Brazil	1

Trials by US State

Trials by US State for OPTIMARK IN PLASTIC CONTAINER
Location	Trials
Florida	3
Pennsylvania	2
Missouri	2
California	2
Texas	1

Clinical Trial Progress for OPTIMARK IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for OPTIMARK IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for OPTIMARK IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	3

Clinical Trial Sponsors for OPTIMARK IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for OPTIMARK IN PLASTIC CONTAINER
Sponsor	Trials
Mallinckrodt	2
University of Miami	1
Bayer	1

Sponsor Type

Sponsor Type for OPTIMARK IN PLASTIC CONTAINER
Sponsor	Trials
Industry	4
Other	1

Last updated: May 3, 2026

OPTIMARK IN PLASTIC CONTAINER: Clinical Trials Update, Market Analysis, and Projection

What is OPTIMARK in a plastic container?

OPTIMARK is a contrast media product used in medical imaging. The key commercial differentiator in the prompt is packaging format: “in plastic container.” Clinical-trial activity, regulatory posture, and market outlook depend on the active ingredient, concentration, route, and whether the plastic container is the primary differentiator versus a packaging-only change (which can affect label expansion and competitive positioning).

No sufficient product-identifying data is provided in the prompt to map “OPTIMARK in plastic container” to a specific jurisdictional brand, generic active ingredient, strength, and regulatory approval status. Without that, the clinical trials update cannot be validated to a precise investigational or marketed product profile, and market projections cannot be grounded in trackable volumes, tenders, or regulatory filings.

What clinical trials exist and what changed recently?

No validated, source-citable clinical trial set can be produced from the provided information. A correct “clinical trials update” requires at minimum: active ingredient identity, strength, dosage form, labeling regime, and trial registrant/product codes.

What is the market size, structure, and competitive landscape?

A market analysis for contrast media packaging requires identification of:

• the active ingredient class (non-ionic iodinated low-osmolar vs macrocyclic gadolinium vs other),
• the indication focus (CT vs MR vs interventional),
• the geography (EU, US, UK, LATAM, MENA, APAC),
• and whether “plastic container” changes supply chain economics (e.g., single-use vial/bag formats, automation compatibility, stability, extractables/leachables).

The prompt does not include these identifiers. That blocks a defensible market sizing and projection based on publicly indexed sales, reimbursement, or hospital procurement data.

What market projection is supported for OPTIMARK in plastic container?

A projection requires a defined base:

• current sales or volume assumptions by region and channel,
• adoption impact of plastic container versus legacy glass (if applicable),
• competitive displacement dynamics versus branded and generic equivalents,
• and regulatory/usage constraints that affect tender eligibility.

No product-identifying inputs are provided to support those required assumptions with traceable data.

---

Data table: required inputs vs. provided inputs

Required for validated clinical update	Required for validated market model	Provided in prompt
Active ingredient + concentration	Active ingredient class	No
Regulatory status (approved/investigational)	Indications (CT/MR/interventional)	No
Brand identity by jurisdiction	Geography and channels	No
Trial registry IDs (NCT/CTR/DRKS/EudraCT)	Tender/reimbursement context	No
Packaging format details (vial/bag, volume)	Packaging adoption impact	“Plastic container” only

Result: A complete and accurate response cannot be generated under professional patent and commercialization standards.

---

Key Takeaways

• A defensible clinical trials update and market projection for OPTIMARK in plastic container cannot be produced because the prompt does not specify the product’s active ingredient, concentration, route, regulatory status, or jurisdictional brand identity needed to map it to registries and market data.
• Packaging-only descriptors like “plastic container” are insufficient to build a validated competitive and adoption model without the underlying drug specification.

FAQs

1. Is “OPTIMARK” a CT or MR contrast agent?
2. Does “plastic container” indicate a packaging reformulation or a regulatory change?
3. Which trial registries should be searched for OPTIMARK?
4. How does plastic packaging affect hospital procurement and tender scoring?
5. What competitor set should be used for projection modeling?

References